2023
Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
Chatur S, Vaduganathan M, Claggett B, Desai A, Docherty K, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mcmurray J, Solomon S. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal 2023, 44: ehad655.751. DOI: 10.1093/eurheartj/ehad655.751.Peer-Reviewed Original ResearchUrgent HF visitsHeart failureHF eventsHF hospitalizationHF visitsEjection fractionFirst presentationSubsequent mortalityComposite endpointSubsequent deathEffect of dapagliflozinTreatment effectsBackground HospitalizationCV causesCV deathDose uptitrationPrimary endpointPrognostic importanceClinical trialsFirst manifestationLandmark analysisAmbulatory careHospitalizationClinical relevancePatients
2020
Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT)
Pareek M, Byrne C, Vaduganathan M, Biering-Sorensen T, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2731. DOI: 10.1093/ehjci/ehaa946.2731.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressureSerum bicarbonate levelsBlood pressureBaseline bicarbonateBicarbonate levelsCV causesAntihypertensive treatmentSystolic blood pressure 130End-stage renal diseaseStandard antihypertensive treatmentHigh cardiovascular riskChronic kidney diseaseGlomerular filtration rateRisk of deathStandard blood pressureLow bicarbonate levelsYears of ageMultivariable adjustmentCardiovascular riskSerum bicarbonateRenal diseaseLaboratory variablesPrognostic implicationsIntervention trialsBaseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT)
Byrne C, Pareek M, Biering-Soerensen T, Vaduganathan M, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2732. DOI: 10.1093/ehjci/ehaa946.2732.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressure loweringBlood pressure loweringSerum potassium levelsIntensive blood pressureSerum potassiumPressure loweringPotassium levelsCV causesMultivariable adjustmentBlood pressureSystolic blood pressure 130End-stage renal diseaseBaseline serum potassiumLong-time mortalityShort-time mortalityStandard antihypertensive treatmentHigh cardiovascular riskHigh-risk patientsGlomerular filtration rateYears of ageSerum potassium measurementsAntihypertensive treatmentCardiovascular riskRenal function
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply